

Reference values for IGF-I serum concentrations: Comparison of six immunoassays

P. Chanson, A. Arnoux, M. Mavromati, S. Brailly-Tabard, C. Massart, J.

Young, M.-L. Piketty, J.-C. Souberbielle

▶ To cite this version:

P. Chanson, A. Arnoux, M. Mavromati, S. Brailly-Tabard, C. Massart, et al.. Reference values for IGF-I serum concentrations: Comparison of six immunoassays. Journal of Clinical Endocrinology and Metabolism, 2016, 101 (9), pp.3450–3458. 10.1210/jc.2016-1257. hal-01380421

HAL Id: hal-01380421 https://univ-rennes.hal.science/hal-01380421

Submitted on 18 Oct 2016

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés. Reference values for insulin-like growth factor I (IGF-I) serum concentrations:
 comparison of six immunoassays.

3 (Short title : Reference values for IGF-I with 6 immunoassays)

4

5 Philippe Chanson, Armelle Arnoux, Maria Mavromati, Sylvie Brailly-Tabard,
6 Catherine Massart, Jacques Young, Marie-Liesse Piketty, and Jean-Claude Souberbielle
7 for the VARIETE Investigators*.

8

9

10 Assistance Publique-Hôpitaux de Paris, Hôpitaux universitaires Paris-Sud, Hôpital de 11 Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction and Centre de 12 Référence des Maladies Endocriniennes Rares de la Croissance (P.C., M.M., J.Y.), and Unité 13 de Recherche Clinique (A.A.), and Service de Génétique Moléculaire, Pharmacogénétique et 14 Hormonologie (S.B.T), Le Kremlin-Bicêtre, F94275, France; Inserm 1185 (P.C., S.B.T., 15 J.Y.), Fac Med Paris Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, F-94276, France; and 16 Centre Hospitalier Universitaire de Rennes, Centre d'Investigation Clinique plurithématique, 17 Inserm 1414, Hôpital Pontchaillou, Laboratoire d'Hormonologie (C.M.), Rennes, F29000, 18 France; and Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Service 19 des Explorations Fonctionnelles (M-L.P., J-C.S.), Paris, F75015, France 20 * a complete list of the VAleurs de Référence de l'IGF-I Et Transformation En Z-score 21 (VARIETE) study investigators is given in Supplemental Appendix 22 23 24 Corresponding author and reprint requests:

25 Philippe Chanson, MD

26	Service d'Endocrinologie et des Maladies de la Reproduction,
27	Hôpital de Bicêtre, 78 rue du Général Leclerc, 94275 Le Kremlin-Bicêtre, France
28	E-mail: philippe.chanson@bct.aphp.fr
29	
30	Abbreviations: BMI, body mass index; IGFBP, IGF binding protein; SDS, standard
31	deviation score.
32	
33	Key terms: IGF-I, Z-score, SD score, normative data, reference range, normal healthy
34	population, acromegaly, growth hormone deficiency
35	
36	Disclosure: The authors have no conflicts of interest to disclose
37	
38	Word count (for text only): 3581
39	
40	Abbreviated title: Reference intervals for serum IGF-I
41	

43 Summary

Context. Measurement of IGF-I is essential for diagnosis and management of patients with
disorders affecting the somatotropic axis. However, even when IGF-I kit manufacturers
follow recent consensus guidelines, different kits can give very different results for a given
sample.

48 Objectives. We sought to establish normative data for six IGF-I assay kits, based on a large49 random sample of the French general adult population.

50 Subjects and Methods: In a cross-sectional multicenter cohort study (ClinicalTrials.gov 51 Identifier: NCT01831648), we measured IGF-I in 911 healthy adults (18-90 years) with six 52 immunoassays (iSYS, LIAISON XL, IMMULITE, IGFI RIACT, Mediagnost ELISA, and 53 Mediagnost RIA). Pairwise concordance between assays was assessed with Bland-Altman 54 plots for both IGF-1 raw data and standard deviation scores (SDS), as well as with the 55 percentage of observed agreement and the weighted Kappa coefficient for categorized IGF-I 56 SDS.

Results: Normative data included the range of values (2.5 to 97.5 percentiles) given by the six
IGF-I assays according to age group and sex. A formula for SDS calculation is provided.
While the lower limits of the reference intervals of the six assays were similar, the upper
limits varied markedly. Pairwise concordances were moderate to good (0.38 to 0.70).

Conclusion. Despite being obtained in the same healthy population, the reference intervals of
the six commercial IGF-1 assay kits showed noteworthy differences. Agreement between
methods was moderate to good.

64

66 Growth hormone (GH) exerts its effects on target tissues either directly or *via* the production 67 of insulin-like growth factor 1 (IGF-I). Accurate measurement of IGF-I in serum is crucial for diagnosis and management of disorders affecting the somatotropic axis, particularly GH 68 69 excess (acromegaly) and GH deficiency (GHD). However, even if manufacturers follow the 70 recommendations of the Consensus Group on the Standardization and Evaluation of GH and 71 IGF-I Assays (1), the different commercial IGF-I assay kits can give very different results for 72 the same sample, with up to a 2.5-fold difference between the lowest and highest values (2). 73 This inter-method variability is generally explained by calibration against different IGF-I 74 reference preparations (3), and differences in the efficiency of methods used to remove IGF-75 binding proteins (IGFBPs) (4). In theory, this should not be a problem in clinical practice, as 76 kits that give higher values should have higher normal limits, and patients should thus be 77 consistently classified.

78 However, it is very difficult to establish reference values for IGF-I. Indeed, serum IGF-I 79 concentrations increase with children's age and pubertal stage, while they fall with age in 80 adults (5). Furthermore, the distribution of IGF-I values in an apparently healthy population is 81 non Gaussian, and this necessitates complex mathematical transformation to obtain reference 82 intervals for each age group. For this reason, it is essential to generate reference values after stratifying a large healthy population into age groups. Another problem is that IGF-I 83 84 concentrations are influenced by many factors other than GH concentrations, including 85 nutritional status and BMI, use of hormone replacement therapy by post-menopausal women, 86 depending on the administration route (6-8), kidney and liver function, and diabetic status (9). 87 Reference IGF-I values may therefore be influenced by the inclusion criteria used to select the 88 reference population sample. This could have important implications for diagnosis and 89 therapeutic decision-making, as a given patient could be classified as having a normal IGF-I 90 concentration with one method but an abnormal value with another method. Several studies

91 suggest that the main reason for inter-laboratory variability in patient classification is the use 92 of different populations to establish reference values for the different IGF-I assays (2,10,11). 93 It is currently difficult to monitor an individual patient with different IGF-I assays, even if the 94 results are all expressed in the same units (ng/ml). It is thus recommended to establish 95 specific reference ranges for each assay, and to apply common, well-defined inclusion criteria 96 to the reference population (1). It is also recommended, for the comparison of values obtained 97 with different assays in the same patient, to express each IGF-I result as an SD score (SDS) 98 with reference to the normative data for the assay in question, after appropriate transformation for data non normality. We reasoned that the best way to overcome this variability would be 99 100 to apply all the commercial kits used in clinical laboratories to a battery of samples from the 101 same well-defined reference population, and to use the same mathematical transformation to 102 calculate reference ranges from the raw data.

103 The aim of this study was thus to establish normative data for six commercial IGF-1 assays in 104 a large random sample of healthy subjects from the French general population representing all 105 adult age groups (about 100 subjects per decade), as recommended by the Consensus Group 106 on the Standardization and Evaluation of GH and IGF-I assays (1). Serum samples from the 107 reference population were tested with six commercial assay kits available in France at the 108 time of this study, after careful exclusion of subjects with medical conditions or medications 109 that might affect their IGF-I concentration. The data were analyzed to obtain the range (2.5 to 110 97.5 percentiles) in mass units. The standard deviation scores were used to compare the six 111 assays.

- 113 Subjects and Methods
- 114 IGF-I assay characteristics

Six immunoassays (iSYS, LIAISON XL, IMMULITE, IGFI RIACT, Mediagnost ELISA, and Mediagnost RIA) were used to measure the IGF-I concentration in each healthy subject. The main characteristics of the assays, and the mathematical models used to determine normative data, where relevant (12-14), are shown in Table 1.

119

120 Healthy subjects

121 The subjects were part of a large cohort of French healthy adults (VARIETE). The VARIETE 122 cohort was an open, prospective, national, multicenter, non randomized study of healthy 123 volunteers, designed to establish normative data for IGF-I and other hormones in the French 124 general adult population representing all age groups (about 100 subjects per decade from 18 125 to 90 years) (ClinicalTrials.gov Identifier: NCT01831648). A total of 972 healthy subjects 126 with BMI values between 19 and 28 kg/m² were recruited in 10 centers throughout France 127 between 2010 and 2011. Our objective of including 1000 subjects was not achieved due to 128 difficulties for obtaining an accurate number of subjects in the older age categories (>70 129 years) fulfilling all the inclusion criteria and without exclusion criteria before the end of our 130 inclusion period. Subjects with medical conditions or medications that might affect IGF-I 131 serum levels were excluded (see Supplemental Appendix). Each subject had a clinical 132 examination, personal medical history-taking and general examination, including careful 133 evaluation of nutritional and gonadal status. Standard laboratory tests (plasma sodium, 134 potassium, calcium, phosphate and creatinine, glycemia, total cholesterol, liver enzymes, 135 TSH, blood cell count, albuminemia, prothrombin time, as well as HIV and HCV serologies) 136 were then performed, and 80 mL of blood (50 mL without anticoagulant and 30 mL in 137 EDTA-containing tubes) was sampled and promptly centrifuged (2000 g, 4° C). Serum and 138 plasma were aliquoted, frozen, and stored at -80°C until hormone measurements.

All healthy subjects gave their written informed consent to participate in the study, which wasapproved by the Paris-Sud Ethics committee before the beginning of the study.

141

142 Statistical methods

The distribution of IGF-1 values obtained with each assay was skewed, and was thus first normalized by means of sex- and age-specific Box-Cox power transformation. Student's *t* test and Levene's test were then used to assess equality of means and homogeneity of variances between men and women in each age group. As men and women had significantly different IGF-1 levels, centile curves were constructed separately for each sex.

148 Age- and sex-specific centile curves were constructed for each assay by using the LMS 149 method (12) implemented in the GAMLSS software package version 4.3-1 (15) of R software 150 version 3.1.2 (2014-10-31) (R Core Team (2014). R: A language and environment for 151 statistical computing. R Foundation for Statistical Computing, Vienna, Austria.URL 152 http://www.R-project.org/.). The LMS method enables smooth curves to be estimated for 153 percentiles after normalization (by Box-Cox power transformation) and standardization of the 154 data. The parameters L (for skewness), M (for median) and S (for the coefficient of variation) 155 were also computed for each age and sex class. SD scores (SDS) were calculated as z = $[(IGF-1 / M)^{L}-1]/(L \times S)$, where IGF-I is the raw value given by the assay (in ng/mL). For 156 157 each technique, SDS were categorized as low, normal or high according to their positions relative to both the 2.5th and 97.5th percentiles. 158

159 Once the L, M and S parameters for each category of age and sex had been obtained, the 160 lower and upper reference interval limits were determined for each assay by fixing z at -1.96 161 and 1.96, respectively, and then mathematically back-transforming the SD score formula.

162 Pairwise concordance between assays was assessed with scatter plots and Bland-Altman plots

163 for both IGF-1 raw values and SDS values, as well as with the percentage of observed

164	agreement (total number of agreements divided by the total number of patients tested with
165	both assays) and the linearly weighted Kappa coefficient for categorized IGF-1 SDS (16,17).
166	An overall kappa coefficient (16) and Friedman's test were computed for global comparison
167	of all assays at the same time. Landis and Koch's table was followed for interpretation of
168	Kappa values (18).
169	Unless otherwise stated, SAS software was used for all statistical analyses (Statistical
170	Analysis System, version 9.4, SAS Institute, Cary, N.C., USA).

- 171
- 172 **Results**
- 173
- 174 *1- Description of the population*

175 Nine hundred seventy-two subjects were initially recruited, of whom 52 were excluded 176 because of abnormal values in the standard laboratory screening tests. A further 9 subjects 177 were excluded because of missing information on pregnancy status or viral serology. The 178 study population thus consisted of 911 subjects (470 males), comprising respectively 101, 179 118, 99, 98, 103, 102, 108, 97 and 85 subjects in the 18-20, 21-23, 24-26, 27-29, 30-39, 40-180 49, 50-59, 60-69, 70-89 year age groups. Mean BMI was 23.0 ± 2.4 kg/m².

181

182 2- IGF-I reference intervals obtained with the six assays

The IGF-I reference intervals (2.5th-97.5th percentiles) obtained with the six immunoassays are shown in Table 2 according to age and sex. Supplemental Figure 1 shows individual points and fitted percentiles (2.5%, 50% and 97.5%) for males and females in each IGF-I assay.

187 A calculator available online (<u>http://ticemed_sa.upmc.fr/sd_score/)</u> or by using Apps (IGF-I

188 SD_score) downloadable for Android from Google Play and for iOS from Apple Store (free

of charge) allows to obtain individual IGF-I SDS after entering the name of the assay, theindividual IGF-I value obtained with the assay, and the sex and age of the individual.

The six reference intervals for males and females are plotted on the same graph in Figure 1.
While the lower limits of the reference intervals (2.5th percentiles) were similar, the upper
limits (97.5th percentiles) varied markedly from one assay to another.

194 **3-** Comparison of IGF-I levels given by the six assays

The results obtained with each IGF-I assay were compared with those obtained with each of the other five assays. Scatter plots and Bland-Altman plots based on raw values and SDS for each pair of assays are shown in Supplemental Figure 2

Whatever the assay, IGF-I concentrations were generally higher in women than in men until the age of 59 years (this was significant for the age ranges 18-20 and 24-26 years). From the age of 60 years, IGF-I levels were slightly higher in men than in women, although the gender difference was smaller than in the younger age groups and was only significant for Immulite, Mediagnost Elisa and Mediagnost RIA.

Two examples of inter-assay comparisons are shown in Figure 2. The results obtained with iSYS and Mediagnost RIA were in good overall agreement, with no significant bias as assessed by Bland-Altman plots (Figure 2 A, B, C and D). In contrast, the results obtained with LIAISON XL and Mediagnost RIA were not in good agreement (Figure 2 E, F, G and H).

Pairwise assay concordances assessed with the weighted Kappa coefficient for categorized
IGF-1 SDS are shown in Table 3. The concordances were moderate to good (0.38 to 0.70),
although the percentages of observed agreement were quite high (94% to 97%).

Overall agreement was moderate as overall Kappa coefficient was 0.55. Both in men and women, global inter-assay comparison showed significant differences (p<0.0001) on raw values but not on SDS values (p=0.26 and p=0.36, respectively).

Table 4 shows pairwise concordances between the reference intervals provided by the manufacturer and those obtained in the VARIETE cohort, as assessed by the Kappa coefficient and the percentage agreement for each IGF-I assay. The concordances and percentages of observed agreement were generally poor.

218

219 **Discussion**

220 We report reference intervals for IGF-I concentrations obtained with six 221 immunoassays in the same population of nearly 900 French healthy subjects aged from 18 to 222 90 years, in keeping with the 2011 recommendations of the Consensus Group on the 223 Standardization and Evaluation of GH and IGF-I assays (1). The population comprised about 224 100 subjects per age decade, and specific reference intervals were calculated for each sex and 225 age group. The reference intervals varied from one assay to another: the lower limits of the normal range (2.5th percentile) were quite similar with the six methods, but the upper limits 226 227 (97.5th percentile) varied widely from one assay to another, in both men and women (Figure 228 1). Although the pre-analytic conditions were the same for the six kits, and although four of 229 the six kits were calibrated against the international reference standard 02/254, concordance 230 between the assays, as assessed with Bland-Altman plots and the Kappa coefficient, remained 231 quite variable, not only for raw IGF-I values but also for IGF-I SDS. This latter result was 232 somewhat surprising, as we expected that, by using the same healthy population, we would 233 obtain similar SDS.

In table 2, which shows the reference ranges for each assay, we have deliberately omitted the mean and SD calculated for each age category from the raw values, in order to avoid erroneous calculations of SDS. Indeed, the Box-Cox power transformation, which is necessary because of the non Gaussian distribution in each age category, uses parameters (L for skewness, M for median and S for the coefficient of variation) that are specific to each

-/22-

assay and also to each age group and gender. We thus propose an online calculator available
either following this link (<u>http://ticemed_sa.upmc.fr/sd_score/</u>) or by using Apps (IGF-I
SD_score) downloadable for Android from Google Play and for iOS from Apple Store (free
of charge) which allows to determine SDS as a function of the assay method, the measured
IGF-I value, gender, and age. L, M and S parameters are also provided in Supplemental Table
1.

245 Reliable reference intervals are crucial for interpreting IGF-I values in adults with 246 acromegaly (for diagnosis and assessment of disease control during treatment), and also for 247 diagnosing GH deficiency and monitoring GH therapy (4,5,19,20). Reference intervals 248 obtained with the IGF-I Nichols Advantage assay in a very large population of healthy 249 subjects (21) were once widely used for research and clinical practice. However, market 250 withdrawal of this assay, together with the availability of numerous automated methods with 251 considerable heterogeneity, led to calls for improved comparability and reliable normative 252 data. One important first step was the creation of the recombinant international IGF-I standard 253 preparation 02/254 (22). A consensus conference held in 2011 proposed that all assays be 254 calibrated against this standard, and advocated precise pre-analytical and analytical conditions 255 (1). Another recommendation was to establish normative data based on a random selection of 256 individuals from the background population, with representation of all age groups (1). The 257 first normative data for the iSYS IGF-I assay, based on these recommendations and on a very 258 large healthy population, were published by Bidlingmaier et al (23). We now propose 259 reference intervals for six IGF-I assays also based on a large population of healthy subjects. It 260 should be noted that we used very stringent inclusion criteria. Indeed, despite the large sample 261 size (almost one thousand healthy subjects, with about 100 subjects per age group), all the 262 subjects had a clinical examination, including assessment of gonadal status, and also a careful 263 medical history taking that included ongoing medications. Furthermore, all the subjects had

an extensive standard biological work-up in order to exclude those with disorders capable of influencing IGF-I levels or their measurement. These very strict inclusion and exclusion criteria allow to define a population as "healthy" as possible; however this implies that these normative data will not be strictly applicable to patients with BMI > 28 kg/m^2 or to patients with oral treatment with estrogens.

269 As expected, IGF-I concentrations fell gradually with age in both sexes, irrespective of the 270 assay. Contrary to previous reports (21,23), we found a gender difference, with higher IGF-I levels in women than in men, whatever the assay, until the 5th decade. After 50 years of age, 271 272 however, IGF-I levels were higher in men than in women, as reported elsewhere (21,23). We 273 therefore propose separate normative data for men and women. One possible explanation for 274 the discrepancy between this work and previous reports is that we excluded all subjects 275 receiving steroid hormones such as estrogens. Indeed, oral estrogen is known to lower IGF-1 276 levels (6-8). In premenopausal women, for example, contraceptive pills containing ethinyl 277 estradiol reduce IGF-I levels by up to an average of 30% (24-27). Another explanation might 278 be the size of our population. Indeed, in their study involving a larger number of subjects 279 (15,000), Bidlingmaier et al. did not find differences in terms of gender differences (23).

280 Inter-assay differences in IGF-I reference intervals are a well-known issue that has 281 previously been underlined by one of us (28,29) and by many other researchers 282 (2,11,23,30,31). In this study, as expected, the largest inter-centile intervals (and highest 283 values) were obtained with the two assays calibrated with the old standard IRP 87/518 (IMMULITE and IGFI RIACT). Moreover, the three automated methods (iSYS, Liaison XL 284 285 and IMMULITE), which should theoretically be the most reproducible, did not yield narrower 286 reference intervals. For example, the iSYS automated method and the Mediagnost RIA 287 manual method gave very similar intervals for both men and women in all age groups. Thus, 288 the main source of variation does not appear to be analytical reproducibility. Using the same

289 iSYS method and a similar transformation for normalizing data and constructing specific centile curves in the LMS method, our 2.5th and 97.5th percentiles were generally slightly 290 291 higher and our intervals generally narrower than those reported by Bidlingmaier et al. (23). 292 Although inter-laboratory variability may play a role in these discrepancies, they are likely 293 due mainly to differences in the population samples (our population was smaller, and the 294 inclusion criteria were different). Another issue raised by our study is the poor concordance 295 between our reference intervals and those proposed by the assay manufacturers. Once again 296 this might be related to the use of different background populations: indeed, those used by 297 manufacturers may not fulfill all the criteria recommended by the consensus group in 2011, 298 particularly with respect to their size, the definition of healthy subjects, and the use of 299 hormonal contraceptives (Supplemental Material).

300 Likewise, one obvious explanation for the discordance between assays is the use of different 301 populations to establish reference intervals. This is why we used the same reference 302 population for all the kits. However, although the six assays showed comparable analytical 303 performance in terms of their reproducibility and detection limits (Table 1), and despite the 304 fact that they use the same non-competitive "sandwich" format and similar methods to avoid 305 IGFBP interference (IGF-II addition), the reference values obtained in our well-controlled 306 adult population differed strikingly from one assay to another. Two of the six assays 307 (IMMULITE and IGF-I RIACT) are still calibrated against the old IRR 87/518 standard, 308 whereas the other four are calibrated against the new IRR 02/254 standard, as currently 309 recommended (1). As expected, the former two assays gave the highest upper reference range 310 for both sexes until the age of 50 (Table 2, Figure 1). However, the reference ranges of two 311 differently calibrated kits may be either similar (e.g. LIAISON XL and IGFI RIACT in men), 312 or significantly different (e.g. iSYS lower than IMMULITE) (Table 2). Likewise, reference 313 ranges determined with kits calibrated against the same reference preparation may also be

314 significantly different, even for kits from the same manufacturer (e.g. the RIA and ELISA kits 315 from Mediagnost). It therefore seems likely that the observed differences are related to other 316 analytical factors, such as the efficiency of IGFBP interference removal and the specificity 317 and/or affinity of the antibody used. For example, since the 2.5th percentile is at least similar 318 between the assays, the broadening of the interval for the IMMULITE assay is probably not 319 related to the calibrator, but to relatively higher measurement results at the upper end:an 320 explanation could be that IMMULITE assay preferentially recognizes the high free IGF-I at 321 high concentrations, while the other 2 assays more efficiently remove the impact of BPs.

This could have important implications in patients with disorders affecting their IGFBP profile, such as acromegaly and chronic kidney disease. If confirmed in further studies, this implies that a given individual must be monitored with the same IGF-I assay.

Another limitation of our study is that it lies on a single measurement of IGF-I while it is well known that there is some within-subject variability when an individual is sampled on different days (32,33).

328 What refinements may be expected in the measurement of this very demanding 329 analyte? The LC-MSMS method may prove to be a valid alternative and is now being used to 330 assess inter-laboratory agreement on IGF-I concentrations (34) or for validation of IGF-I 331 measures (35). Reference intervals for IGF-I provided with this LC-MS (36) seem very 332 comparable with those obtained with immunoassays. When compared with our data, lower 333 limit of normal range is similar and upper limit corresponds more or less with those observed 334 with Liaison XL or IGF1 RIACT immunoaasays. However, LC-MSMS is a time-consuming 335 and complex method that requires expensive machines and high technical expertise, because 336 many variables need to be controlled for providing accurate quantitative results 337 (e.g. extraction strategies, approaches to detect and quantify IGF-I, calibration 338 protocols...)(37). Furthermore, a recent preliminary study of an LC-MS method suggested

-/22-

that it might miss some IGF-I protein variants (pathogenic or physiological), which are
present in 0.6% of the population (38). Thus, despite their limitations, immunoassays will
continue to be widely used, at least in the near future (39).

342 In conclusion, we have established reference intervals for six commercial IGF-I 343 assays, in a study conforming to recent international recommendations. Despite being 344 obtained in the same large population of French healthy subjects, the reference intervals 345 differed somewhat from one assay to another, and agreement between assays was moderate to 346 good. Finally, concordances between the manufacturers' reference intervals and those 347 obtained in our cohort were generally poor. These findings confirm the need to establish 348 reference intervals for each commercial IGF-I assay in a large background population. Inter-349 assay concordance with respect to the classification of patients with acromegaly or GH 350 deficiency remains to be determined, and the IGF-I standard deviation scores obtained with 351 the six assays in these subjects need to be compared.

352

353 Acknowledgments

The study was supported by a grant from Programme Hospitalier de Recherche Clinique, French Ministry of Health, N° P081216 / IDRCB 2009-A00892-55 and by a grant from Fond National Suisse, P1GEP3_155694, to Dr Maria Mavromati.

357

358 We thank for Dr Hélène Agostini and Prof. Bruno Falissard for their helpful comments.

We also thank Cisbio International, DiaSorin, IDS, Mediagnost, and Siemens for the kinddonation of IGF-I kits.

362 Legends of Figures

363 **Figure 1.**

Reference intervals (Upper panel, males; lower panel, females) according to the age intervals
of the 6 immunoassays tested. Lower limits (2.5th percentile) and upper limits (97.5th
percentile) of the normal range are drawn as full lines and means as dotted lines.

367

368	Figure	2.
-----	--------	----

369 Comparisons between iSYS and Mediagnost RIA expressed as scatter plots (A) or Bland-

370 Altman plots (B) for raw data, or scatter plots (C) and Bland-Altman plots (D) for SDS

371 showing a good overall agreement between both immunoassays, with no significant bias.

372 Comparisons between Liaison XL and Mediagnost RIA expressed as scatter plots (E) or

373 Bland-Altman plots (F) for raw data, or scatter plots (G) and Bland-Altman plots (H) for SDS

374 showing a bad overall agreement between these two immunoassays.

- 375
- 376
- 377

- Clemmons DR. Consensus Statement on the Standardization and Evaluation of
 Growth Hormone and Insulin-like Growth Factor Assays. Clin Chem 2011; 57:555 559
- Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ. Variation in GH and
 IGF-I assays limits the applicability of international consensus criteria to local
 practice. Clin Endocrinol (Oxf) 2007; 67:65-70
- 388 **3.** Quarmby V, Quan C, Ling V, Compton P, Canova-Davis E. How much insulin-like
- 389 growth factor I (IGF-I) circulates? Impact of standardization on IGF-I assay accuracy.
- 390 J Clin Endocrinol Metab 1998; 83:1211-1216
- Frystyk J, Freda P, Clemmons DR. The current status of IGF-I assays--a 2009 update.
 Growth Horm IGF Res 2010; 20:8-18
- Brabant G, Wallaschofski H. Normal levels of serum IGF-I: determinants and validity
 of current reference ranges. Pituitary 2007; 10:129-133
- Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health
 and disease. Growth Horm IGF Res 2003; 13:113-170
- 397 7. Leung KC, Johannsson G, Leong GM, Ho KK. Estrogen regulation of growth
 398 hormone action. Endocr Rev 2004; 25:693-721
- 399 8. Meinhardt UJ, Ho KK. Modulation of growth hormone action by sex steroids. Clin
 400 Endocrinol (Oxf) 2006; 65:413-422
- 401 9. Clemmons DR. Value of insulin-like growth factor system markers in the assessment
 402 of growth hormone status. Endocrinol Metab Clin North Am 2007; 36:109-129
- 403 10. Massart C, Poirier JY, Jard C, Pouchard M, Vigier MP. Determination of serum
 404 insulin-like growth factor-I reference values for the immunometric Cisbio method on a

- 405 large number of healthy subjects: clinical utility in the follow-up of patients with
 406 treated acromegaly. Clin Chim Acta 2007; 381:176-178
- 407 11. Varewijck AJ, Lamberts SW, van der Lely AJ, Neggers SJ, Hofland LJ, Janssen JA.
 408 The introduction of the IDS-iSYS total IGF-1 assay may have far-reaching
 409 consequences for diagnosis and treatment of GH deficiency. J Clin Endocrinol Metab
 410 2015; 100:309-316
- 411 12. Cole TJ, Green PJ. Smoothing reference centile curves: the LMS method and
 412 penalized likelihood. Stat Med 1992; 11:1305-1319
- 413 13. Blum WF, Breier BH. Radioimmunoassays for IGFs and IGFBPs. Growth Regul
 414 1994; 4 Suppl 1:11-19
- 415 14. Royston P, Wright EM. A method for estimating age-specific reference intervals
 416 based on fractional polynomials and exponential transformation. J Royal Stat Soc:
 417 Series A 1998; 161:79-101
- 418 15. Rigby RA, Stasinopoulos DM. Generalized additive models for location, scale and
 419 shape. Journal of the Royal Statistical Society: Series C (Applied Statistics) 2005;
 420 54:507-554
- 421 16. Fleiss J-L, Levin B, Paik MC. Statistical methods for rates and proportions. Third
 422 Edition ed. New York: Wiley.
- 423 17. Cicchetti DV, Allison T. A new procedure for assessing reliability of scoring EEG
 424 sleep recordings. American Journal of EEG Technology 1971; 11:101-109
- 425 18. Landis JR, Koch GG. The measurement of observer agreement for categorical data.
 426 Biometrics 1977; 33:159-174
- 427 19. Clemmons DR. IGF-I assays: current assay methodologies and their limitations.
 428 Pituitary 2007; 10:121-128

- 429 20. Junnila RK, Strasburger CJ, Bidlingmaier M. Pitfalls of insulin-like growth factor-I
 430 and growth hormone assays. Endocrinol Metab Clin North Am 2015; 44:27-34
- Brabant G, von zur Muhlen A, Wuster C, Ranke MB, Kratzsch J, Kiess W,
 Ketelslegers JM, Wilhelmsen L, Hulthen L, Saller B, Mattsson A, Wilde J, Schemer
 R, Kann P. Serum insulin-like growth factor I reference values for an automated
 chemiluminescence immunoassay system: results from a multicenter study. Horm Res
 2003; 60:53-60
- Burns C, Rigsby P, Moore M, Rafferty B. The First International Standard For
 Insulin-like Growth Factor-1 (IGF-1) for immunoassay: preparation and calibration in
 an international collaborative study. Growth Horm IGF Res 2009; 19:457-462
- 439 23. Bidlingmaier M, Friedrich N, Emeny RT, Spranger J, Wolthers OD, Roswall J,
- Korner A, Obermayer-Pietsch B, Hubener C, Dahlgren J, Frystyk J, Pfeiffer AF,
 Doering A, Bielohuby M, Wallaschofski H, Arafat AM. Reference intervals for
 insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter
- 443 study using a new automated chemiluminescence IGF-I immunoassay conforming to
- recent international recommendations. J Clin Endocrinol Metab 2014; 99:1712-1721
- 445 24. Jernstrom H, Deal C, Wilkin F, Chu W, Tao Y, Majeed N, Hudson T, Narod SA,
 446 Pollak M. Genetic and nongenetic factors associated with variation of plasma levels of
 447 insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy
- 448 premenopausal women. Cancer Epidemiol Biomarkers Prev 2001; 10:377-384
- Elkazaz AY, Salama K. The effect of oral contraceptive different patterns of use on
 circulating IGF-1 and bone mineral density in healthy premenopausal women.
 Endocrine 2015; 48:272-278

-/22-

- 452 26. Blackmore KM, Wong J, Knight JA. A cross-sectional study of different patterns of
 453 oral contraceptive use among premenopausal women and circulating IGF-1:
 454 implications for disease risk. BMC Womens Health 2011; 11:15
- 455 27. Balogh A, Kauf E, Vollanth R, Graser G, Klinger G, Oettel M. Effects of two oral
 456 contraceptives on plasma levels of insulin-like growth factor I (IGF-I) and growth
 457 hormone (hGH). Contraception 2000; 62:259-269
- 458 28. Massart C, Poirier JY. Serum insulin-like growth factor-I measurement in the follow459 up of treated acromegaly: comparison of four immunoassays. Clin Chim Acta 2006;
 460 373:176-179
- 461 29. Massart C, Poirier JY. Determination of serum insulin-like growth factor-I reference
 462 values for the automated chemiluminescent Liaison(R) assay. Clinical utility in the
 463 follow-up of patients with treated acromegaly. Clin Chim Acta 2011; 412:398-399
- 464 30. Krebs A, Wallaschofski H, Spilcke-Liss E, Kohlmann T, Brabant G, Volzke H, Nauck
 465 M. Five commercially available insulin-like growth factor I (IGF-I) assays in
 466 comparison to the former Nichols Advantage IGF-I in a growth hormone treated
 467 population. Clin Chem Lab Med 2008; 46:1776-1783
- 468 31. Cowan DA, Bartlett C. Laboratory issues in the implementation of the marker method.
 469 Growth Horm IGF Res 2009; 19:357-360
- 470 32. Milani D, Carmichael JD, Welkowitz J, Ferris S, Reitz RE, Danoff A, Kleinberg DL.
 471 Variability and reliability of single serum IGF-I measurements: impact on determining
 472 predictability of risk ratios in disease development. J Clin Endocrinol Metab 2004;
 473 89:2271-2274
- 474 33. Nguyen TV, Nelson AE, Howe CJ, Seibel MJ, Baxter RC, Handelsman DJ,
 475 Kazlauskas R, Ho KK. Within-subject variability and analytic imprecision of

- 476 insulinlike growth factor axis and collagen markers: implications for clinical diagnosis477 and doping tests. Clin Chem 2008; 54:1268-1276
- 478 34. Cox HD, Lopes F, Woldemariam GA, Becker JO, Parkin MC, Thomas A, Butch AW,
 479 Cowan DA, Thevis M, Bowers LD, Hoofnagle AN. Interlaboratory agreement of
 480 insulin-like growth factor 1 concentrations measured by mass spectrometry. Clin
 481 Chem 2014; 60:541-548
- 482 35. Kay R, Halsall DJ, Annamalai AK, Kandasamy N, Taylor K, Fenwick S, Webb A,
 483 Wark G, Pleasance S, Gurnell M. A novel mass spectrometry-based method for
 484 determining insulin-like growth factor 1: assessment in a cohort of subjects with
 485 newly diagnosed acromegaly. Clin Endocrinol (Oxf) 2013; 78:424-430
- 486 36. Bystrom C, Sheng S, Zhang K, Caulfield M, Clarke NJ, Reitz R. Clinical utility of
 487 insulin-like growth factor 1 and 2; determination by high resolution mass
 488 spectrometry. PLoS One 2012; 7:e43457
- 489 37. Hoofnagle AN, Whiteaker JR, Carr SA, Kuhn E, Liu T, Massoni SA, Thomas SN, 490 Townsend RR, Zimmerman LJ, Boja E, Chen J, Crimmins DL, Davies SR, Gao Y, 491 Hiltke TR, Ketchum KA, Kinsinger CR, Mesri M, Meyer MR, Qian WJ, Schoenherr 492 RM, Scott MG, Shi T, Whiteley GR, Wrobel JA, Wu C, Ackermann BL, Aebersold R, 493 Barnidge DR, Bunk DM, Clarke N, Fishman JB, Grant RP, Kusebauch U, Kushnir 494 MM, Lowenthal MS, Moritz RL, Neubert H, Patterson SD, Rockwood AL, Rogers J, 495 Singh RJ, Van Eyk JE, Wong SH, Zhang S, Chan DW, Chen X, Ellis MJ, Liebler DC, 496 Rodland KD, Rodriguez H, Smith RD, Zhang Z, Zhang H, Paulovich AG. 497 Recommendations for the Generation, Quantification, Storage, and Handling of 498 Peptides Used for Mass Spectrometry-Based Assays. Clin Chem 2016; 62:48-69

-/22-

- 499 38. Hines J, Milosevic D, Ketha H, Taylor R, Algeciras-Schimnich A, Grebe SK, Singh
 500 RJ. Detection of IGF-1 protein variants by use of LC-MS with high-resolution
 501 accurate mass in routine clinical analysis. Clin Chem 2015; 61:990-991
 502 40 H. d. H. Gi, J. DL Gi, J. D. Gi, J. D. Gi, J. J. Chem 2015; 61:990-991
- 502 39. Ketha H, Singh RJ. Clinical assays for quantitation of insulin-like-growth-factor-1
- 503 (IGF1). Methods 2015; 81:93-98

Table 1 :Characteristics of the tested IGF-I assays as provided by the manufacturers. These 6 assays are sandwich assays that use a couple of monoclonal antibodies directed against epitopes whose exact nature is not disclosed by the manufacturers. In all cases, IGFBPs are said to be removed by displacement of endogenous IGF-I by an excess of IGF-II (or analog) as initially proposed by Blum and Breier (13). The limit of quantification (LOQ) is the lowest amount of IGF-I that can be accurately quantified with an allowable error $\leq 20\%$. The limit of detection (LOD) is the IGF-I concentration corresponding to the 95th percentile value from a number of determinations of IGF-I concentration in free serum samples.

Name of the assay	Manu- facturer	Auto mated	Tracer	International standard against which the assay is calibrated	Intra-assay CV	Inter-assay CV	LOQ or LOD in ng/mL	Highest measurab le value without dilution (ng/mL)	Reference adult population recruited by the manufacturer
iSYS	IDS	Yes	Acridinium ester	WHO/NIBSC 02/254	2.9% at 22 ng/mL 1.9% at 163 ng/mL 4.2% at 304 ng/mL	5.4% at 22 ng/mL 3.9% at 163 ng/mL 7.2% at 304 ng/mL	8.8 (LOQ)	1200	6500 adults. Reference values provided according to the method of Cole and Green) (12)
LIAISON XL	DiaSorin	Yes	isoluminol	WHO/NIBSC 02/254	5.1% at 70 ng/mL 3.5% at 183 ng/mL 3% at 589 ng/mL	9.6% at 80 ng/mL 7.1% at 187 ng/mL 5.6% at 317 ng/mL	3 (LOD) 10 (LOQ)	1500	1606 adults. Reference values provided by age according to the method of Royston and Wright (14)
IMMULITE 2000	Siemens	Yes	Alkaline phosphatase	WHO/NIBSC 1 st IRR 87/518	3.9% at 77 ng/mL 6.5% at 169 ng/mL 2.9% at 380 ng/mL 3.0% at 689 ng/mL 2.3% at 1053 ng/mL 2.4% at 1358 ng/mL	7.7% at 77 ng/mL 5.4% at 169 ng/mL 7.4% at 380 ng/mL 8.1% at 689 ng/mL 3.7% at 1053 ng/mL 4.7% at 1358 ng/mL	20 (LOQ)	1600	1499 pediatric and adult samples from an apparently healthy population (no indication is given concerning the respective numbers of adult and children)
IGFI- RIACT	Cisbio	No	¹²⁵ I	WHO/NIBSC 1 st IRR 87/518	3.8% at 49 ng/mL 3.4% at 162 ng/mL 3.2% at 496 ng/mL	3.8 % at 39 ng/mL 8.2 % at 352 ng/mL 5.9 % at 509 ng/mL	1 (LOD)	900	693 adults 29-70 years
Mediagnost ELISA	MEDIA- GNOST	No	Peroxydase enzyme conjugate	WHO/NIBSC 02/254	5.7% at 138 ng/mL 5.1% at 141 ng/mL 6.6% at 145 ng/mL	6.1 % at 142 ng/mL 6.8 % at 174 ng/mL 2.2 % at 494 ng/mL	1.9 (LOD)	1050	Based on the data reported by Blum and Breier (13)
Mediagnost RIA	MEDIA- GNOST	No	¹²⁵ I	WHO/NIBSC 02/254	4.6% at 56 ng/mL 3.4% at 140 ng/mL 2.5% at 180 ng/mL	4.9 % at 55 ng/mL 6.2 % at 140 ng/mL 4.5 % at 186 ng/mL	2.6 (LOD)	780	Based on the data reported by Blum and Breier (13) The reference values for the different age ranges are the same as those used for the Mediagnost ELISA kit

iSYS LIAISON XL **IMMULITE 2000 IGFI-RIACT** Mediagnost ELISA Mediagnost RIA Age range Ν IGF-I (ng/mL) IGF-I (ng/mL) IGF-I (ng/mL) IGF-I (ng/mL) IGF-I (ng/mL) IGF-I (ng/mL) 95%CI 95%CI 95%CI 95%CI 95%CI 95%CI Males 186-453 195-537 197-486 177-430 168-374 18-20 years 168-391 56 147-346 168-411 171-477 173-430 159-388 150-337 21-23 years 61 24-26 years 132-313 153-377 152-430 155-389 144-355 135-308 53 122-292 142-351 138-396 133-331 126-289 27-29 years 143-363 49 108-265 118-348 124-310 115-295 112-265 30-39 years 127-329 56 40-49 years 91-233 106-271 98-301 107-286 98-261 97-237 51 81-214 97-252 85-273 94-262 88-245 86-218 50-59 years 54 60-69 years 75-208 92-245 77-260 87-250 80-237 82-214 49 70-89 years 64-192 80-220 66-242 75-231 71-233 72-200 34 Females 180-586 169-517 18-20 years 155-421 191-483 169-487 161-412 41 21-23 years 144-383 176-448 166-541 159-476 156-446 149-379 54 134-353 163-418 153-501 150-440 144-412 139-353 24-26 years 45 126-330 152-391 142-467 142-410 134-385 131-332 27-29 years 48 113-294 131-345 121-403 126-356 118-341 118-298 30-39 years 47 97-253 40-49 years 109-296 98-331 107-297 100-296 103-258 50 80-209 80-271 90-247 82-248 93-253 97-220 50-59 years 54 60-69 years 68-208 64-170 84-222 68-227 76-209 75-190 47 70-89 years 56-154 81-204 60-188 67-189 60-187 68-175 50

Table 2.Normative reference intervals (95% confidence interval : CI) of IGF-I measured by 6 assay methods according to age range and sex in a cohort of 899 healthy subjects


	LIAISON XL	iSYS	IMMULITE 2000	Mediagnost ELISA	Mediagnost RIA	IGFI- RIACT
LIAISON XL	-	0.49 94.86%	0.50 94.83%	0.47 94.95%	0.38 94.05%	0.48 95.22%
iSYS	0.49 94.86%	-	0.64 96.08%	0.61 96.11%	0.70 97.00%	0.64 96.46%
IMMULITE 2000	0.50 94.83%	0.64 96.08%	-	0.61 95.95%	0.58 95.73%	0.64 96.32%
Mediagnost ELISA	0.47 94.95%	0.61 96.11%	0.61 95.95%	-	0.59 96.00%	0.53 95.66%
Mediagnost RIA	0.38 94.05%	0.70 97.00%	0.58 95.73%	0.59 96.00%	-	0.48 95.22%
IGFI- RIACT	0.48 95.22%	0.64 96.46%	0.64 96.32%	0.53 95.66%	0.48 95.22%	-

Table 3. Agreement of each IGF-1 assay method against each of the other, expressed as weighted kappa and percentages of observed agreement.


Table 4. Concordance between VARIETE cohort reference intervals and reference intervals provided by each manufacturer, expressed as Kappa and percentages of observed agreement

	LIAISON XL	iSYS	IMMULITE 2000	Mediagnost ELISA	Mediagnost RIA	IGFI - RIACT
Weighted Kappa	0.19	0.35	0.38	0.18	0.17	0.22
% of agreement	83.28	93.36	86.97	93.55	94.77	88.21

А



в



Click here to access/download Supplemental Material Supplemental material VF .docx

Click here to access/download Supplemental Material Suppl Table 1.docx

Click here to access/download Supplemental Material Suppl Figure 1VF.docx

Click here to access/download Supplemental Material Suppl Figure 2VF.docx